LGM
Logos Global Management Portfolio holdings
AUM
$749M
This Quarter Return
+31.06%
1 Year Return
+18.94%
3 Year Return
+431.72%
5 Year Return
+481.1%
10 Year Return
–
AUM
$950M
AUM Growth
+$50.8M
(+5.7%)
Cap. Flow
+$2.46M
Cap. Flow
% of AUM
0.26%
Top 10 Holdings %
Top 10 Hldgs %
52.34%
Holding
74
New
23
Increased
9
Reduced
10
Closed
20
Top Buys
| 1 |
Sarepta Therapeutics
SRPT
|
$51.8M |
| 2 |
Immunocore
IMCR
|
$32.5M |
| 3 |
Geron
GERN
|
$29.7M |
| 4 |
Celldex Therapeutics
CLDX
|
$27.3M |
| 5 |
Vera Therapeutics
VERA
|
$24.8M |
Top Sells
| 1 |
Cytokinetics
CYTK
|
$107M |
| 2 |
argenx
ARGX
|
$55.2M |
| 3 |
RYZB
RayzeBio, Inc. Common Stock
RYZB
|
$35.3M |
| 4 |
AMAM
Ambrx Biopharma, Inc. Common Stock
AMAM
|
$29.9M |
| 5 |
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
|
$28.5M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Viridian Therapeutics
VRDN
$1.59B
| $12.3M | 0.99% |
700,000
+100,000
| +17% | +$1.75M |
|
27
Cullinan Oncology
CGEM
$456M
| $11.9M | 0.97% |
+700,000
| New | +$11.9M |
|
28
Immatics
IMTX
$662M
| $10.5M | 0.85% |
+1,000,000
| New | +$10.5M |
|
29
Spyre Therapeutics
SYRE
$1.02B
| $9.48M | 0.77% |
250,000
+100,000
| +67% | +$3.79M |
|
30
Lineage Cell Therapeutics
LCTX
$281M
| $9.25M | 0.75% |
+6,250,000
| New | +$9.25M |
|
31
Praxis Precision Medicines
PRAX
$980M
| $9.15M | 0.74% |
+150,000
| New | +$9.15M |
|
32
Applied Therapeutics
APLT
$73.7M
| $8.98M | 0.73% |
1,350,000
-310,000
| -19% | -$2.06M |
|
33
Syndax Pharmaceuticals
SNDX
$1.39B
| $8.33M | 0.67% |
+350,000
| New | +$8.33M |
|
34
Trevi Therapeutics
TRVI
$871M
| $7.59M | 0.61% |
+2,200,000
| New | +$7.59M |
|
|
35
Cytokinetics
CYTK
$5.98B
| $7.01M | 0.57% |
100,000
-1,525,000
| -94% | -$107M |
|
36
Kura Oncology
KURA
$732M
| $6.4M | 0.52% |
+300,000
| New | +$6.4M |
|
37
Neumora Therapeutics
NMRA
$283M
| $6.19M | 0.5% |
382,345
| – | – |
|
|
ATYR
38
aTyr Pharma
ATYR
$560M
| $6.05M | 0.49% |
3,100,000
-2,750,000
| -47% | -$5.36M |
|
39
Janux Therapeutics
JANX
$1.38B
| $5.65M | 0.46% |
+150,000
| New | +$5.65M |
|
|
ELEV
40
DELISTED
Elevation Oncology
ELEV
| $5.13M | 0.42% |
+1,000,000
| New | +$5.13M |
|
41
NextCure
NXTC
$13.3M
| $4.29M | 0.35% |
+160,417
| New | +$4.29M |
|
|
ALLK
42
DELISTED
Allakos
ALLK
| $3.65M | 0.3% |
2,900,000
| – | – |
|
43
Unicycive Therapeutics
UNCY
$75.8M
| $3.01M | 0.24% |
+346,993
| New | +$3.01M |
|
|
BOLD
44
Boundless Bio
BOLD
$25.7M
| $2.85M | 0.23% |
+200,000
| New | +$2.85M |
|
45
Tourmaline Bio
TRML
$645M
| $2.27M | 0.18% |
99,208
-185,164
| -65% | -$4.24M |
|
|
CMPS
46
Compass Pathways
CMPS
$452M
| $1.81M | 0.15% |
257,980
-242,020
| -48% | -$1.7M |
|
47
IO Biotech
IOBT
$115M
| $854K | 0.07% |
493,827
| – | – |
|
48
Immunic
IMUX
$79.4M
| $556K | 0.05% |
421,184
| – | – |
|
49
Leap Therapeutics
LPTX
$12M
| $105K | 0.01% |
+39,500
| New | +$105K |
|
50
Nuvation Bio Inc. Redeemable warrants, each whole warrant exercisable for one share of Class A common stock at an exercise price of $11.50
NUVB.WS
$63.9M
| $22.7K | ﹤0.01% |
66,666
| – | – |
|